Want to see BMY full AI Analyst Report?
BMY Stock Chart & Stats
$64.72
$0.57(0.89%)
At close: 4:00 PM EDT
$64.72
$0.57(0.89%)
Day’s Range― - ―
52-Week Range$42.52 - $68.64
Previous Close$64.12
Volume7.21M
Average Volume (3M)12.62M
Market Cap
$120.17B
Enterprise Value$151.99B
Total Cash (Recent Filing)$11.07B
Total Debt (Recent Filing)$43.12B
Price to Earnings (P/E)13.2
Beta0.22
Next Earnings
Oct 29, 2026EPS Estimate
1.1Next Dividend Ex-DateN/A
Dividend Yield4.28%
Share Statistics
EPS (TTM)4.54
Shares Outstanding2,042,714,600
10 Day Avg. Volume14,364,394
30 Day Avg. Volume12,621,209
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue3.09
Enterprise Value/Gross Profit4.40
Enterprise Value/Ebitda9.04
Forecast
1Y Price Target
$66.60Price Target Upside2.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)6.31
Revenue Forecast (FY)$49.90B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And ProfitabilityRobust operating and free cash flow demonstrate that reported earnings are substantially backed by cash, supporting debt service, investment in the pipeline, and shareholder returns. Healthy gross and operating margins also provide resilience as the company manages product-cycle changes.
Growth Portfolio Momentum And Raised GuidanceA growing portfolio representing nearly 60% of quarterly revenue is helping offset mature-product pressure and indicates improving portfolio mix. Raised guidance, supported by multiple products with double-digit growth, strengthens confidence in near-term commercial execution.
Pipeline Expansion Through Differentiated TherapiesPositive Phase 3 data and orphan designation could advance RYZ101 toward regulatory submission in an area described as having significant unmet need. This adds a potentially differentiated growth asset and broadens BMS’s future oncology revenue base.
Bears Say
Elevated Financial LeverageElevated leverage reduces financial flexibility if profitability or product cycles weaken, while increasing the importance of sustained cash generation for debt service. Although the balance-sheet trend is improving, the capital structure remains less defensive than desired.
Legacy Portfolio Erosion And Future Eliquis Step-downGeneric competition and the expected Eliquis decline create a durable revenue headwind that the growth portfolio must overcome. This pressure can dilute consolidated growth, reduce operating leverage, and increase dependence on successful launches and indications.
Clinical Timing And Commercial Execution RisksDelayed trial readouts postpone regulatory and commercial catalysts, while Cobenfy’s dosing behavior may limit uptake until education and Phase IV work improve execution. Together, these issues increase uncertainty around the timing and scale of pipeline replacement.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $42.52 and its highest was $68.64 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $120.17B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Jul 30, 2026. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.597 by $0.443.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.63 which represents an annual dividend yield of 4.28%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.1.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,042,714,600 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $2.04 in its last earnings report, beating expectations of $1.597. Following the earnings report the stock price went up 2.789%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$66.60 (2.90% Upside)
$66.60 (2.90% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 87%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $437.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.83%
12-Months-Change
Fundamentals
Return on Equity
46.75%
Trailing 12-Months
Asset Growth
-7.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
BMY Company Deck
BMY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive commercial and pipeline narrative: solid top-line growth (+5% revenue, growth portfolio +14%), multiple high-growth products (several >20% and one >80%), raised full-year guidance, strong cash generation and balance sheet, and meaningful pipeline and regulatory milestones (multiple PDUFAs, pivotal readouts upcoming). Key risks include timing delays for event-driven trials (milvexian and parts of the ADEPT program), legacy portfolio pressure from generics, an Opdivo revenue decline, and the need for improved Cobenfy dosing optimization. On balance, the highlights—strong current commercial execution, upgraded guidance, and significant pipeline/launch potential—outweigh the operational and timing challenges described.View all BMY earnings summariesBMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$66.60
▲(2.90% Upside)
Technical Analysis
Ownership Overview
0.03% Insiders
18.66% Mutual Funds
0.99% Other Institutional Investors
52.25% Public Companies and Individual Investors